Our analysis also shows that beta-blockers could also have anti-fibrotic and anti-inflammatory effects in post-MI LV remodeling with myocyte-specific enhancer factors (MEF2A, MEF2C, MEF2D), endothelins (EDN and EDNRA) and a series of chemokines, such as CXCL1, CXCL2, and IL-8, as mediators. The gene discussed is MEF2A; the disease is myocardial infarction.